

DANIEL GRIFFIN, MD, PhD CTropMed CTH

23 Murray Ave
Port Washington, NY 11050
Cell# (347)-276-6116
DanielGriffinMD@gmail.com

Daniel Griffin



1-PREPARATION OF CV: August 23, 2024

PROFILE: A physician-scientist, board certified in Internal Medicine and Infectious Disease with expertise in Global Health, Tropical Medicine, Parasitology, and Virology, including SARS-CoV2 (COVID-19). An active clinician and internationally invited speaker lecturing for multiple organizations, including the University of Glasgow, the Peace Corp, University of Minnesota, Foundation for International Medical Relief of Children (FIMRC), Floating Doctors, and Remote Care Education, as well as for other groups in Asia, the Caribbean, Central America, Africa, and India. One of the hosts of the popular podcasts *This Week in Parasitism*, *This Week in Virology*, and *The IDPuscast*. One of the authors of *Parasitic Diseases*, now in its 7th Edition with thousands of copies distributed to over 100 countries throughout the world.

2-PERSONAL DATA

Name: Daniel Griffin
Birth date: July 15, 1967
Birthplace: New York, NY
Citizenship: USA

3-ACADEMIC APPOINTMENTS, HOSPITAL APPOINTMENTS, and other WORK EXPERIENCE

INFECTIOUS DISEASE PHYSICIAN 1/1/2017-CURRENT

Optum Distinguished Partner
Chief, Division of Infectious Disease
Infectious Diseases and Travel Medicine
OPTUM TRI-STATE (Formerly ProHealth Care NY)
1 Dakota Drive, Suite 205
Lake Success, NY 11042
Tel: (516)-656-6500

- Chief of Division at Optum Tristate, the largest Care Delivery Organization (CDO) for United Health Group (UHG), the largest employer of physicians in the United States with >70,000 physicians. Clinical Practice focusing on inpatient and outpatient infectious disease consultations, care of HIV-infected individuals, patients with general Infectious Diseases, COVID, Long COVID, and Travel Medicine.

COLUMBIA UNIVERSITY IRVING MEDICAL CENTER-4/23/2014-**CURRENT**

Instructor of Clinical Medicine/Infectious Disease Specialist

DEPARTMENT OF MEDICINE-DIVISION OF INFECTIOUS DISEASES

Associate Research Scientist

DEPARTMENT OF BIOCHEMISTRY & MOLECULAR BIOPHYSICS (4/23/2014-6/30/2020)

630 West 168th Street

New York, NY 10032-3723

Ph# +1 (646) 724-1061 (Contact Glendaly Menendez gm336@cumc.columbia.edu)

- Clinical Practice focusing on teaching and supervision of fellows, residents, and medical students in the care of inpatient and outpatient HIV-infected individuals and patients with general Infectious Diseases. Division Head Magdalena Sobieszczyk
- Research on HIV and stem cell latency, Human HSPC lentiviral gene therapy, mechanisms driving B cell malignancies in HIV patients, HIV-associated malignancies, SARS-CoV2, COVID, and Long COVID, innate immune sensing of cytosolic nucleic acids such as foreign DNA and RNA, Zika viral infection and assays of human stem and progenitor cells, avian malaria impacts on exotic birds, iron metabolism and diagnostics in rhinos and lemurs, cytoskeletal trafficking impacts on viral trafficking using electroporation and lipid based introduction of mRNA and siRNA into human hematopoietic stem and human progenitor cells

PARASITES WITHOUT BORDERS, Inc. 6/3/2016-**CURRENT**

President-Director

23 Murray Ave

Port Washington, NY, 11050

Tel: (888)-963-8970

info@parasiteswithoutborders.com

- A comprehensive, advanced educational resource and disseminator of basic and clinical information dealing with all aspects of the global problems associated with acquiring parasitic diseases that adversely affect people worldwide. Providing textbooks and producing lectures on parasitic diseases and global health issues. >40,000 textbooks to >100 countries throughout the world

MicrobeTV 2019-**CURRENT**

Director

Daniel@microbe.tv

- A science education organization producing multiple podcasts, including This Week in Virology, This Week in Parasitism, This Week in Microbiology, This Week in Neuroscience, This Week in Evolution, Urban Agriculture, Virus Watch, ID Puscast, and Immune
- Co-Host on This Week in Parasitism, This Week in Virology, and the ID Puscast

HOSPITAL APPOINTMENTS

CURRENT

New York Presbyterian Columbia University Medical Center-Consultation Privileges

7/1/2015-Current

630 West 168th Street

New York, NY 10032

Plainview Hospital Infectious Disease Consultation Privileges

1/2017-current

888 Old Country Road, Plainview, NY 11803

Medical Staff Office (516)-823-8855

North Shore University Hospital-Infectious Disease Consultation Privileges

9/16/2009-6/30/2013, 1/2017-current

300 Community Dr, Manhasset, NY 11030

Medical Staff Office (516)-823-8855

Long Island Jewish Hospital- Infectious Disease Consultation Privileges

9/16/2009-6/30/2013, 2/17/2015-11/2015, 1-2017-current

270-05 76th Ave, New Hype Park, NY 11040

Medical Staff Office (516)-823-8855

Syosset Hospital Infectious Disease Consultation Privileges

1/2017-current

221 Jericho Turnpike, Syosset, NY 11791

Medical Staff Office (516)-823-8855

LIJ-Valley Stream Hospital Infectious Disease Consultation Privileges

11/14/2017-current

900 Franklin Ave, Valley Stream, NY 11580

Medical Staff Office (516)-823-8855

Saint Francis Hospital

07/24/2018 -current

100 Port Washington Boulevard

Roslyn, NY 11576

Medical Staff Office (516)-562-6000

Saint Joseph Hospital

06/16/2020-current

4295 Hempstead Turnpike

Bethpage, NY 11714

Medical Staff Office (516)-520-2387

PRIOR

Providence Alaska Medical Center-Internal Medicine Privileges

6/25/2010-2/2/2012

3200 Providence Dr, Anchorage, AK 99508

ph# (907) 212-3185, fax# (907) 212-4865 Debra.Wilsack@providence.org

Alaska Regional Hospital-Internal Medicine Privileges

12/1/2009-3/29/2012

2801 DeBarr Rd, Anchorage, AK 99508

ph# (907)-264-1261, fax# (907) 264-1143 kerry.gardner@hcahealthcare.com

Poudre Valley Hospital-Internal Medicine Privileges

6/23/1999-7/31/2009

1024 S Lemay Ave, Fort Collins, CO 80524

ph#970-495-7153 fax#970-495-7639 morgan.lael@uchealth.org

PRIOR EMPLOYMENT

SENIOR INFECTIOUS DISEASE FELLOW

United Health Group 2/2020-6/2022

UHG Global Research and Development

Minnetonka, MN 12700

- Senior Infectious Disease Advisor position at the 4th largest company in the world, largest healthcare company in the world, on its Medicare Advantage Program, Design, and Execution of Clinical Trials, support for protein and mRNA-based vaccines, educational programs, and guidance on support and implementation of protein and mRNA-based COVID-19 vaccines, PI on clinical trials, design, and consultation on development and delivery of monoclonal antibodies, and development and delivery of Education Programs, Therapeutics, Testing, and Infection Control.

INFECTIOUS DISEASE ATTENDING-7/1/2014-10/6/2015

HOFSTRA-NORTHSHORE-LIJ SCHOOL OF MEDICINE

DIVISION OF INFECTIOUS DISEASE

400 Community Drive,

Manhasset, NY 11030

(516) 562-4280

- Clinical training and responsibilities for outpatient and inpatient care of individuals with various infectious diseases. Research focusing on mortality in patients infected with retroviral infection (HIV).

ELMEZZI SCHOLAR and TEACHING ATTENDING INTERNAL MEDICINE RESIDENCY

PROGRAM* ELMEZZI SCHOOL OF MOLECULAR MEDICINE /FEINSTEIN INSTITUTE/NSLIJ

HEALTH SYSTEM 9/2/2008-5/24/2012

350 Community Drive,

Manhasset, NY 11030

(516) 562-1159

- Research focused on innate B cells' role in Cancer, Infectious diseases, Degenerative Diseases,

and Autoimmune Diseases. Published that Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+CD70-. Identified that a small CD11b+ human B1 cell subpopulation stimulates T cells and is expanded in lupus. Identified that Human "orchestrator" CD11b(+) B1 cells spontaneously secrete IL-10 and regulate T cell activity. Performed single-cell sorting of Human B1 cells, amplification of mRNA encoding natural antibody immunoglobulins, cloning into DNA expression plasmids with the production of mRNA resulting in production of cloned natural antibodies. Work on 'natural antibodies' produced by Human B1-cells and their targets for developing passive and active immunization strategies using protein-based, attenuated viral, DNA, and mRNA-based vaccine technologies for infectious diseases, malignancies, and neurodegenerative diseases.

- PROBONO: Caring for patients and supervising and teaching Medical Students and Internal Medical Residents in an indigent clinic setting.

OWNER AND PRIMARY CARE PHYSICIAN*ALPENGLOW MEDICAL 8/21/1999-6/27/2008
1006 Robertson St, Fort Collins, CO 80525
(970) 482-3820

- The sole owner of this five-physician General Internal Medicine Clinic with management and clinical responsibilities. This clinic was the highest volume Inpatient/Outpatient Internal Medicine clinic in Fort Collins, with yearly collections approaching 2 million dollars. This clinic had over 30,000 patient visits per year with an average personal volume of 30 outpatient visits/day plus inpatient census ranging from 3-8 patients/day. Responsibilities also included supervising physician assistants and nurse practitioners, working with Residents, teaching medical students, and developing clinical practice guidelines. (8/1998-8/1999 choosing a location and setting up a clinic with patient care started 9/1999)

RESEARCH ASSISTANT

Memorial Sloan Kettering (MSK) Kettering Laboratory 6/1991-8/1991 and 6/1992-8-1992

- Worked on renal cancer and melanoma doing DNA and RNA extractions, nucleic acid analysis, sequencing and sequence analysis, and polymerase chain reaction before the introduction of thermocyclers

-PRIOR SECONDARY EMPLOYMENT

ALASKA HOSPITALIST GROUP
6/25-6/27/2010 and 11/13-16/2010
4800 Cordova St #100 Anchorage, AK 99503
(907)-375-3355

- Worked shifts in Anchorage as a hospitalist physician, admitting and managing inpatients at Providence Hospital and Alaska Regional Hospital

HIMSS DAVIES AWARD SELECTION COMMITTEE
Member 9/1/2006-12/31/2009
Chair 1/1/2010-6/30/2012

PRESIDENT * NORTHERN COLORADO IPA
9/1/2006-4/30/2008
1175 58th Ave., Greeley, CO 80634
970-495-0333

- President of the Largest Independent Practice Association in Colorado with over 500 physician members. Responsible for leadership in developing, implementing, and monitoring clinical practice guidelines and contract negotiations for more than 250 million dollars in clinical contracts with health insurers. Oversaw and managed the capitated risk contract covering Northeastern Colorado, Southeastern Wyoming, and Western Nebraska.

MEDICAL DIRECTOR*NORTHERN COLORADO IPA

9/1/2003-4/31/2008

1175 58th Avenue, Suite 202, Greeley, CO 80634

970-495-0333

- Chair of QAI and Chair of Contracting Committee; Responsible for negotiating all organization insurance contracts, credentialing new and renewing members, and head of Quality Assurance assessment and enforcement.

MEDICAL DIRECTOR * PREFERRED HOMECARE

2004 – 2006

6835 Sherman Street, Loveland, CO 80538

(970) 356-5317

- Review and oversight of all clinical care performed by personnel.

MEDICAL DIRECTOR*SPRING CREEK HEALTH CENTER

2002-2003

1000 East Stuart Street Fort Collins, CO 80525

(970) 482-5712

- Review and oversight of all clinical care performed by personnel.

MEDICAL DIRECTOR*CORRECTIONAL HEALTH MANAGEMENT INC, FORT COLLINS, CO

2001-2002

2255 Midpoint Drive, Fort Collins, CO 80525

970-498-7000

Review of all clinical care at the facility and the development of treatment protocols.

OWNER & MEMBER-MANAGER*HARVEST MOON INVESTMENT

2/12/2001-4/3/2008

1006 Robertson Street, Fort Collins, CO 80525

(970) 482-3820

- Responsible for management of this commercial real estate company with over a million dollars in assets, multiple tenants, and commercial building holdings.

COLLABORATING PHYSICIAN AND BUSINESS CONSULTANT*LIFESPAN FAMILY CARE

2002-2006

1217 Riverside Avenue, Fort Collins, CO 80524

(970) 484-9533

- Responsible for developing the business plan and ongoing assistance in running this first free-standing, independent nurse practitioner clinic in Colorado, as well as clinical oversight and teaching responsibilities for nurse practitioners and students.

HOSPITALIST*FORT HARRISON VETERANS HOSPITAL HELENA, MT 1997-1998
1900 Williams Street, Helena, MT 59602
(406) 442-6410

- Sole weekend coverage for the entire facility includes ER, clinic, general patient, ICU, and periodic weekend shifts.

PHYSICIAN CONSULTANT*ALPENGLOW MEDICAL CONSULTING
7/1999-2008

- Consultant for research, development, translational medicine, and marketing for several pharmaceutical and biotech companies and local and regional speaker for multiple pharmaceutical and biotech companies, including AMGEN, GSK, ROCHE, Boehringer Ingelheim, Novartis, and Proctor and Gamble on the topics of Hypertension, Congestive Heart Failure, and Osteoporosis.
- *Medical Director of Primary Care Osteoporosis Division - Amgen* (Tasked with development of novel osteoporosis therapy based on the RANKL osteoclast pathway, development of a monoclonal antibody, preclinical testing and clinical trials, obtaining FDA approval, and then marketing – resulted in the development of Denosumab-(Prolia-Xgeva).

4-EDUCATION

UNIVERSITY OF MINNESOTA GLOBAL HEALTH COURSE: Clinical Tropical, Migrant and Travel Medicine completed August 2016

-(8-module course including overseas module in southeast Asia-ASTMH approved course for eligibility to take the ASTMH Examination in Clinical Tropical Medicine and Traveler's Health via the Diploma Course pathway)

(PHD) IN MOLECULAR MEDICINE 9/1/2008-6/30/2012 Completed
ELMEZZI GRADUATE SCHOOL OF MOLECULAR MEDICINE/THE FEINSTEIN
INSTITUTE/NSLIJHS
IDENTIFICATION OF THE PHENOTYPE OF THE HUMAN B1 CELL
-350 Community Dr, Manhasset, NY 11030 ph# (516) 562-3405 fax# (516) 562-1022
email: ehristis@nshs.edu

CERTIFICATE IN THE BUSINESS OF MEDICINE 11/1/1998-6/30/2000 Completed
JOHNS HOPKINS CAREY BUSINESS SCHOOL – 100 International Drive, Baltimore MD, 21202
ph# 410-234-9200

(MD) MEDICINE DEGREE 9/3/1990-5/26/1995 Completed
NEW YORK UNIVERSITY SCHOOL OF MEDICINE - 550 1st Ave, NY, NY 10016 ph# (212) 263-7300

(BA) IN PHILOSOPHY 9/2/1986-8/12/1989 Completed
UNIVERSITY OF COLORADO, BOULDER 2055 Regent Drive, Boulder, CO 80302
ph#303-492-1411

MAJOR IN PHILOSOPHY MINOR MATHEMATICS 9/3/1985-8/22/1986
UNIVERSITY MIAMI -1320 South Dixie Hwy, Coral Gables, FL 33146

5-POSTGRADUATE MEDICAL TRAINING

FELLOWSHIP IN INFECTIOUS DISEASE 7/1/2012-6/30/2014 Completed

NORTHSHORE-LIJ HEALTH SYSTEM/HOFSTRA NORTHSHORE-LIJ SCHOOL OF MEDICINE
AT HOFSTRA UNIVERSITY -400 Community Drive, Manhasset, NY 11030 ph# (516) 562-3045
email: jmacdonald@nshs.edu

- Advanced training in performing Infectious Disease evaluations and consultations. Ongoing research looking at the incidence of malignancies in patients living with HIV, factors associated with mortality in patients living with HIV, and risks associated with co-infections in patients living with HIV. Work on 'natural antibodies' produced by Human B1-cells and their targets for developing passive and active immunization strategies using protein-based, attenuated viral, DNA, and mRNA-based vaccine technologies for infectious diseases, malignancies, and neurodegenerative diseases.

CATEGORICAL INTERNAL MEDICINE RESIDENCY 7/1/1995-6/30/1998 Completed

UNIVERSITY OF UTAH - SALT LAKE CITY, UTAH. 30 North 1900 East, Salt Lake City, UT 84132 Phone: (801) 581-7606, Fax: (801) 581-5393

- Clinical training in both hospital-based and outpatient care of adult general medical patients. Ongoing research looks at the identified human homolog of the murine mycobacterial resistance protein, natural resistance-associated macrophage protein 1 (NRAMP1), coded by the SLC11A1 gene. This involved isolation, amplification, sequencing, and the analysis of genetic material (mRNA and DNA) from blood spots obtained from children in Dar es Salaam, Tanzania, with cerebral malaria. Studied the role of the role of genes involved in disease enhancement seen in cerebral malaria with attention to the role of nitric oxide regulation.

6-EMPLOYMENT/TRAINING/EDUCATION GAPS

After graduating from university in 8/1989 until 9/30/1990, I started a moving company (Cheap and Gentle Movers) and worked while I applied to Medical School. In December 1990, I took a leave of absence from Medical School (failed marital engagement and financial challenges), returned to classes 9/1991, and completed my degree. In July 1998, I started a research ID fellowship at U of CO (7/1/98-8/14/98), but financial and staff issues for the University prevented them from providing the protected research time. I then interviewed for positions and spent the rest of this year setting up a private practice that opened in August 1999. July 2008-August 2008, I moved my family to NY after selling my Practice in CO.

7-LICENSURE and BOARD CERTIFICATIONS

- New York Medical License#246745 dates-11/07/2007-current until 06/30/2025
- BOARD CERTIFIED in INFECTIOUS DISEASE (ABIM) 10/28/2014-current (certification through 2024)
- BOARD CERTIFIED INTERNAL MEDICINE-DIPLOMATE OF THE AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) 10/28/1998-(recertified-2008 and 2018) current (certification through 12/31/2028) and current maintenance of certification (MOC)
- CERTIFIED in TRAVEL MEDICINE (CTM)-INTERNATIONAL SOCIETY OF TRAVEL MEDICINE (ISTM) 8/2/2014-current certification through 12/31/2024
- ASTMH CERTIFICATE OF KNOWLEDGE IN CLINICAL TROPICAL MEDICINE AND TRAVELER'S HEALTH (CTropMed) 11/12/2016

8-HONORS & AWARDS

- Optum Sages of Clinical Services Award 2023
- Lawrence Scherr Award for Scholarly Activity 2014 First Place
- Infectious Disease Society of New York: First Place Basic Science Category 2014
- Lawrence Scherr Award for Scholarly Activity 2013 Second Place
- Ruth and Leonard Litwin Fellowship Award 2011 – In recognition of an Outstanding Investigator in Medical Research
- Malcolm Baldrige National Quality Award 2008 awarded to Poudre Valley while serving as chair of Medicine and after tenure as Vice Chair of Medicine and Head of Hospital Quality Assurance
- Davies Award-2006 Winner (Best Implementation of an Electronic Health Record in an Ambulatory Clinic) International award given by HIMSS, the largest health IT organization in the world
- Denver Business Journal Physician Champion Award 2007 - Recognized as one of the top state Physician Champions (One of three physicians recognized for their contributions to innovating healthcare in the state)
- DOQ-IT Best Practice Award 2005 (Doctor's Office Quality Information Technology)- recognized as a model of 'best practice' due to best patient outcomes nationally, efficiency, and electronic record implementation by CMS 2005
- CMS – Recognized as having clinical outcomes for CMS performance measures in the top 1 percent for any practitioner in the country 2005
- Colorado Foundation for Medical Care/CMS- speaker for the first Transformational Grand Rounds (National Teleconference on practice management and single piece flow) ‘Single-Piece Flow in a Physician’s Office-Interview with the Flute Player’
- Medical Records Institute (Host of TEPR) speaker for the EMR ROADSHOW
- NYU School of Medicine Independent Research Project Award 1995 (Work on identifying the human homolog of the murine NRAMP gene associated with resistance to mycobacterial infection. Involved in generating and screening DNA libraries, sequencing, and sequence analysis. Collaborations looking at approaches to induce gene expression with consideration of DNA and mRNA introduction to introduce or regulate gene expression using nucleic acid-coated gold beads (gene gun), nonviral lipid-mediated gene delivery, and other techniques)

9-LEADERSHIP and ACADEMIC SERVICE

- OPTUMCARE NATIONAL ID/VACCINES COMMITTEE 2020-**CURRENT**
 - Regularly review and generation of vaccine and therapeutic recommendations for care delivery organizations across the U.S.
- OPTUM/UHG NATIONAL COVID-19 ADVISORY COMMITTEE 2020-**CURRENT**
 - Regular review and presentation at the national level of research results, guidance and presentation, and creation of guidance and educational documents
- AMERICAN SOCIETY of HEMATOLOGY 6/18/2020-**CURRENT**
 - ASH Guideline Panel on the Use of Anticoagulation in Patients With COVID-19

Infectious Disease Physician nominated by the Infectious Disease Society of America to serve on this panel, creating evidence-based graded recommendations for the use of anticoagulation in patients with COVID-19

- NSLIJ HEALTH SYSTEM INSTITUTIONAL REVIEW BOARD (IRB)
 - Voting Member 2009-2011
- MEDICAL DIRECTOR * NORTHERN COLORADO IPA
 - 9/1/2003-4/31/2008. Responsible for developing, implementing, and monitoring clinical practice guidelines and quality monitoring of members, including reviewing all malpractice cases.
- CHAIR OF MEDICINE DEPARTMENT * POUDRE VALLEY HOSPITAL
 - 1/1/2008-3/31/2008
1024 S. Lemay Avenue, Fort Collins, CO 80524
(970) 495-7000
Chair of the Department of Medicine the year the facility was awarded the *Malcolm Baldrige National Quality Award 2008*.
- VICE CHAIR OF MEDICINE DEPARTMENT/HEAD OF HOSPITAL QUALITY ASSURANCE COMMITTEE * POUDRE VALLEY HOSPITAL
1/1/2006-12/31/2007
1024 S. Lemay Avenue, Fort Collins, CO 80524
(970) 495-7000
Chair of the QAI committee and responsible for developing system improvements resulting in improvements of publicly reported measures and improvements in individual practitioners' performance. I served during the two years immediately before 2008 when the facility was awarded the Malcolm Baldrige National Quality Award 2008.
- MEMBER OF HOSPITAL QAI * POUDRE VALLEY HOSPITAL
9/1/1999-12/31/2005
1024 S. Lemay Avenue
Fort Collins, CO 80524
(970) 495-7000
Internal Medicine Representative on QAI committee with responsibility for monitoring individual practitioner's performance.

10-PROFESSIONAL ORGANIZATIONS, SOCIETIES and SERVICE

- AMERICAN MEDICAL ASSOCIATION (AMA) Lifetime member
- AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE (AAAS) member
- INFECTIOUS DISEASES SOCIETY OF AMERICA (IDSA) member
- AMERICAN SOCIETY OF TROPICAL MEDICINE AND HYGIENE (ASTMH) member
- INTERNATIONAL SOCIETY FOR TRAVEL MEDICINE (ISTM) member
- AMERICAN SOCIETY OF PARASITOLOGISTS (ASP) member
- WILDERNESS MEDICAL SOCIETY (WMS) Lifetime member
- AMERICAN SOCIETY OF MICROBIOLOGY (ASM) member

JOURNAL REVIEWER (multiple journals, examples)

- Journal of AIDS & Clinical Research
- International Journal of Tropical Disease & Health
- CDC Emerging Infectious Diseases
- Mayo Clinic Proceedings
- The BMJ
- The International Journal of Pathogen Research
- American Journal of Tropical Medicine & Hygiene

11-FELLOWSHIP and GRANT SUPPORT

Past-Completed Research Support

Donald and Barbara Zucker Family Foundation Grant Griffin (PI) 1/1/2015-6/30/2020

Gene therapy utilizing retroviral vectors. Responsibilities: I designed and performed the experiments, procured and isolated cells, and produced pseudotyped viruses for gene transfer.

Role: PI

Howard Hughes Goff (PI) 2013-2014

Investigations into the epidemiology of cancer deaths in HIV+ patients, diagnosis and management of serology-negative human hepatic hydatidosis, and preliminary work on lentiviral restriction in human HSCs. Responsibilities: I designed and performed the experiments with guidance and mentorship from Stephen Goff and members of his lab.

Role: Post-Doc/Infectious Disease Fellow

Ruth and Leonard Litwin Fellowship Award Griffin (PI) 2012

Publication of methods for determining Human B1 cell frequency and isolation and analysis of human B1 cells. Investigations regarding the potential role of human B1 cells and natural antibodies in HIV-associated malignancies. Sequencing and cloning of human B1 cell-derived antibodies targeting phosphorylcholine and abnormally phosphorylated tau protein.

Role: PI

Feinstein General Clinical Research Center (GCRC) Griffin (PI) 2012

Demonstration that Human "orchestrator" CD11b(+) B1 cells spontaneously secrete IL-10 and regulate T cell activity.

Role: PI

Feinstein General Clinical Research Center (GCRC) Griffin (PI) 2011

Isolation of a human homolog of murine B-1 cells, characterization of a small CD11b+ human B1 cell subpopulation that stimulates T cells and evaluating this cell subset in lupus.

Role: PI

Pending Support-none

12-EDUCATIONAL CONTRIBUTIONS

Direct Teaching/Precepting/Supervising

INSTRUCTOR OF CLINICAL MEDICINE DEPARTMENT OF MEDICINE/DIVISION OF INFECTIOUS DISEASES

7/1/2015-CURRENT

Columbia University Medical Center

630 West 168th St PH 8W, Rm 876

New York, NY 10032

(212) 305-7185

- Caring for patients, supervising and teaching Medical Students, Internal Medical Residents, and Infectious Disease Fellows in inpatient and outpatient settings.

TEACHING ATTENDING INTERNAL MEDICINE RESIDENCY PROGRAM/NSLIJ HEALTH SYSTEM 9/2/2008-5/24/2012

350 Community Dr,

Manhasset, NY 11030

(516) 562-1159

- Caring for patients, supervising, and teaching Medical Students and Internal Medical Residents in an indigent clinic setting in Queens, NY.

13-REPORT of CLINICAL and PUBLIC HEALTH ACTIVITIES and INNOVATIONS

- Floating Doctors–March 2022 –primary care to isolated indigenous population on islands of the coast of Northern Panama only accessible by water and presented lectures to volunteers/staff
- Foundation for International Medical Relief of Children (FIMRC) Bududa, Uganda, near the Kenyan border, clinical care and presented lectures to volunteers/staff November 2019
- Floating Doctors/Remote Care Education –March 2019 –primary care to isolated indigenous population on islands of the coast of Northern Panama only accessible by water and presented lectures to volunteers/staff
- Foundation for International Medical Relief of Children (FIMRC) Bududa, Uganda clinical care and presented lectures to volunteers/staff November 2018-December 2018
- Floating Doctors/Remote Care Education –March 2018 –primary care to isolated indigenous population on islands of the coast of Northern Panama only accessible by water
- Remote Care Education March 2018-CURRENT-CME Instructor for program preparing clinicians to practice in remote settings.
- Floating Doctors –October 2017 CURRENT–primary care to isolated indigenous population on islands of the coast of Northern Panama only accessible by water
- Foundation for International Medical Relief of Children (FIMRC) Dominican Republic near the Haitian border, clinical care and teaching November 2016-December 2016
- Foundation for International Medical Relief of Children (FIMRC) 2016-CURRENT providing clinical care and teaching.

14-PATENTS and INVENTIONS

HUMAN B1 CELLS AND USES THEREOF

Application number: 20130202624

Abstract: The present invention is directed to isolated populations of human natural immunoglobulin-producing B1 lymphocytes, wherein the B1 lymphocytes display surface biomarkers CD20, CD43, and CD27 and are either CD11b⁺ or CD11b⁻. The present invention is also directed to isolating human

natural immunoglobulin-producing B1 lymphocytes from a blood sample comprising isolating B lymphocytes from the sample expressing surface biomarkers CD20, CD43, and CD27, and, optionally, CD11b. In addition, the present invention is directed to methods for diagnosing a B1 cell disorder in a patient, determining the prognosis of a patient with a B1 cell disorder, and treating a patient with a B1 cell disorder.

Type: Application

Filed: September 22, 2011

Issued: August 8, 2013

Inventors: Rothstein L. Thomas, Daniel O. Griffin, Nichol E. Holodick

15-PUBLICATIONS

ORIGINAL, PEER-REVIEWED ARTICLES

1. Griffin, DO, Racaniello, VR **COVID-19: A Narrative Review** Editor Invited Article JAMA in process, manuscript record, MS #JAMA24-7556
2. Griffin, DO **Post-Acute Sequelae of COVID (PASC or Long COVID): An Evidenced-based Approach** Accepted as an Editor's Choice Paper and in press OFID.
3. Mr Connor Grady , Dr Bornali Bhattacharjee , Mr Julio Silva , Dr Jillian Jaycox , Dr Lik Wee Lee , Dr Valter Monteiro , Dr Mitsuaki Sawano , Ms Daisey Massey , Dr César Caraballo , Dr Jeff Gehlhausen , Dr Alexandra Tabachnikova , Dr Tianyang Mao , Dr Carolina Lucas , Dr Mario Peña-Hernandez , Dr Lan Xu , Dr Tiffany Tzeng , Dr Takehiro Takahashi , Dr Jeph Herrin , Ms Diana Güthe , Ms Athena Akrami , Ms Gina Assaf , Ms Hannah Davis , Ms Karen Harris , Ms Lisa McCorkell , Dr Wade Schulz , Dr Daniel Griffin , Ms Hannah Wei , Dr Aaron Ring , Dr Leying Guan , Charles Dela Cruz , Professor Harlan Krumholz: **Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID** medRxiv [Preprint]. 2024 Jan 12:2024.01.11.24300929. doi: 10.1101/2024.01.11.24300929. PMID: 38260484; PMCID: PMC10802754. Under review Nature Communications <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10802754/pdf/nihpp-2024.01.11.24300929v1.pdf>
4. Daniel O. Griffin, Chase McNeil, James Okusa, Diana Berrent, Yinglong, Guo, Sarah E Daugherty, **Does Monoclonal Antibody Treatment for COVID-19 Impact Short and Long-term Outcomes in a Large Generalizable Population? A Retrospective Cohort Study in the United States.** Accepted 7/2023 BMJOpen 2023;13:e069247. Doi:10.1136/bmjopen-2022-069247 <https://bmjopen.bmj.com/content/bmjopen/13/8/e069247.full.pdf>
5. Griffin DO*, Islam, N*, Jarvis, MS, Cohen K: **Comparative effectiveness of the sars-CoV-2 vaccines during delta dominance.** (*co-first authors) Heliyon 2023;9(5):e16006. doi: 10.1016/j.heliyon.2023.e16006, DOI: <https://doi.org/10.1016/j.heliyon.2023.e16006> [https://www.cell.com/heliyon/fulltext/S2405-8440\(23\)03213-9?returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2405844023032139%3Fshowall%3Dtrue](https://www.cell.com/heliyon/fulltext/S2405-8440(23)03213-9?returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2405844023032139%3Fshowall%3Dtrue)
6. Adam Cuker, Eric K. Tseng, Holger J. Schünemann, Pantep Angchaisuksiri, Clifton Blair, Kathryn Dane, Maria T. DeSancho, David Diuguid, Daniel O. Griffin, Susan R. Kahn, Frederikus A. Klok, Alfred Ian Lee, Ignacio Neumann, Ashok Pai, Marc Righini, Kristen M. Sanfilippo, Deborah M. Siegal, Mike Skara, Deirdra R. Terrell, Kamshad Touri, Elie A. Akl, Reyad Al Jabiri, Yazan Al Jabiri, Mary Boulos, Romina Brignardello-Petersen, Rana Charide, Luis E. Colunga-Lozano, Karin Dearness, Andrea J. Darzi, Samer G. Karam, Gian Paolo Morgano, Rami Z. Morsi, Binu A. Philip, Yetiani Roldan Benitez, Adrienne Stevens, Karla Solo, Wojtek Wiercioch, Reem A. Mustafa, Robby Nieuwlaet; **American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for**

- patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients.** *Blood Adv* 2022; 6 (17): 4975–4982.
doi: <https://doi.org/10.1182/bloodadvances.2022007940>
7. Griffin DO. **COVID-19: Using the Right Tools at the Right Time.** Medical Research Archives, [S.I.], v.10,n. 8, aug. 2022 ISSN 2375-1924 doi: <https://doi.org/10.18103/mra.v6i83041>, <https://esmed.org/MRA/mra/article/view/3041>
 8. Adam Cuker, Eric K. Tseng, Holger J. Schünemann, Pantep Angchaisuksiri, Clifton Blair, Kathryn Dane, Maria T DeSancho, David L Diuguid, Daniel O. Griffin, Susan R. Kahn, Frederikus A Klok, Alfred I Lee, Ignacio Neumann, Ashok Pai, Marc Righini, Kristen Sanfilippo, Deborah M Siegal, Mike Skara, Deirdra R Terrell, Kamshad Touri, Elie A. Akl, Reyad Nayif Al Jabiri, Yazan Nayif Al Jabiri, Mary Boulos, Romina Brignardello-Petersen, Rana Charide, Luis Enrique Colunga-Lozano, Karin Lee Dearness, Andrea J. Darzi, Samer G. Karam, Gian Paolo Morgano, Rami Z. Morsi, Binu A. Philip, Yetiani Roldan, Adrienne Stevens, Karla Solo, Wojtek Wiercioch, Reem A. Mustafa, Robby Nieuwlaet; **American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19** *Blood Adv*, Jun 24, 2022; bloodadvances.2022007940.PMID 2022007940 doi: <https://doi.org/10.1182/bloodadvances.2022007940>
 9. Cuker A, Tseng EK, Nieuwlaet R, Angchaisuksiri P, Blair C, Dane K, DeSancho MT, Diuguid DL, Griffin DO, Kahn SR, Klok FA, Lee AI, Neumann I, Pai A, Righini M, Sanfilippo K, Siegal DM, Skara M, Terrell DR, Touri K, Akl EA, Al Jabiri RN, Al Jabiri YN, Barbara AM, Bognanni A, Boulos M, Brignardello-Petersen R, Charide R, Colunga-Lozano LE, Dearness KL, Darzi AJ, Hussein H, Karam SG, Mansour R, Morgano GP, Morsi RZ, Muti-Schünemann G, Nadim MK, Philip BA, Qiu Y, Benitez YR, Stevens A, Solo K, Wiercioch W, Mustafa RA, Schünemann HJ. **American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients.** *Blood Adv*. 2022 May 3;bloodadvances.2022007561. doi: 10.1182/bloodadvances.2022007561. PMID: 35503027 <https://pubmed.ncbi.nlm.nih.gov/35503027/>
 10. Gabriel Johnson; Sarah Lim; Daniel O Griffin; Xiong Wang; Lida R Etemad, **The Impact or COVID-19 Monoclonal Antibody Therapy on Progression to Hospitalization in A Population with a High Percentage of the SARS-CoV-2 Alpha Variant** *Medical Research Archives* Feb 2022 vol 10 issue 2. <https://esmed.org/MRA/mra/article/view/2703>
 11. Cuker, A., E. K. Tseng, R. Nieuwlaet, P. Angchaisuksiri, C. Blair, K. Dane, J. Davila, M. T. DeSancho, D. Diuguid, Griffin D. O., S. R. Kahn, F. A. Klok, A. I. Lee, I. Neumann, A. Pai, M. Righini, K. M. Sanfilippo, D. Siegal, M. Skara, D. R. Terrell, K. Touri, E. A. Akl, R. N. Al Jabiri, Y. N. Al Jabiri, A. M. Barbara, A. Bognanni, I. Bou Akl, M. Boulos, R. Brignardello-Petersen, R. Charide, M. Chan, L. E. Colunga-Lozano, K. Dearness, A. J. Darzi, H. Hussein, S. G. Karam, P. Kolb, R. Mansour, G. P. Morgano, R. Z. Morsi, G. Muti-Schünemann, M. K. Nadim, A. Noori, B. A. Philip, T. Piggott, Y. Qiu, Y. R. Benitez, F. Schünemann, A. Stevens, K. Solo, W. Wiercioch, R. A. Mustafa & H. J. Schünemann (2022) **American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis.** *Blood Advances*, Jan 21, 2022, 6, 664-671.
<https://ashpublications.org/bloodadvances/article/6/17/4915/485124/American-Society-of-Hematology-living-guidelines>
 12. Cuker A, Tseng EK, Nieuwlaet R, Angchaisuksiri P, Blair C, Dane K, Davila J, DeSancho MT, Diuguid D, Griffin DO, Kahn SR, Klok FA, Lee AI, Neumann I, Pai A, Righini M, Sanfilippo KM, Siegal D, Skara M, Terrell DR, Touri K, Akl EA, Bou Akl I, Bognanni A, Boulos M, Brignardello-Petersen R, Charide R, Chan M, Dearness K, Darzi AJ, Kolb P, Colunga-Lozano

- LE, Mansour R, Morgano GP, Morsi RZ, Muti-Schünemann G, Noori A, Philip BA, Piggott T, Qiu Y, Roldan Y, Schünemann F, Stevens A, Solo K, Wiercioch W, Mustafa RA, Schünemann HJ. **American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients.** Blood Adv. 2021 Oct 26;5(20):3951-3959. doi: 10.1182/bloodadvances.2021005493. Erratum in: Blood Adv. 2023 Mar 14;7(5):811. PMID: 34474482; PMCID: PMC8416320.
<https://ashpublications.org/bloodadvances/article/5/20/3951/476770/American-Society-of-Hematology-living-guidelines>
13. Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, Davila J, DeSancho MT, Diuguid DL, Griffin DO, Kahn SR, Klok FA, Lee AI, Neumann I, Pai A, Righini M, Sanfilippo K, Siegal DM, Skara M, Terrell DR, Touri K, Akl EA, Al Jabiri RN, Al Jabiri YN, Barbara AM, Bognanni A, Bou Akl I, Boulos M, Brignardello-Petersen R, Charide R, Chan M, Colunga-Lozano LE, Dearness KL, Darzi AJ, Hussein H, Karam SG, Kolb P, Mansour R, Morgano GP, Morsi RZ, Muti-Schünemann G, Nadim MK, Noori A, Philip BA, Piggott T, Qiu Y, Benitez YR, Schünemann F, Stevens A, Solo K, Wiercioch W, Mustafa RA, Schünemann HJ. **American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on post-discharge thromboprophylaxis.** Blood Adv. 2021 February 9, 2021: bloodadvances.2021005945. doi: 10.1182/bloodadvances.2021005945. PMID: 34727173.
<https://pubmed.ncbi.nlm.nih.gov/34727173/>
 14. Binh T. Ngo, Paul Marik, Pierre Kory, Leland Shapiro, Raphael Thomadsen, Jose Iglesias, Stephen Ditmore, Marc Rendell, Joseph Varon, Michael Dubé, Neha Nanda, Gino In, Daniel Arkfeld, Preet Chaudhary, Vito M. Campese, Diana L. Hanna, David E. Sawcer, Glenn Ehresmann, David Peng, Mirosław Smogorewski, April Armstrong, Rajkumar Dasgupta, Fred Sattler, Denise Brennan-Rieder, Cristina Mussini, Oriol Mitja, Vicente Soriano, Nicolas Peschanski, Gilles Hayem, Marco Confalonieri, Maria Carmela Piccirillo, Antonio Lobo-Ferreira, Iraldo Bello Rivero, Eivind H. Vinjevoll, Daniel Griffin, Ivan FN Hung **The Time to Offer Treatments for COVID-19.** Expert Opinion on Investigational Drugs, 23 April 2021, <https://doi.org/10.1080/13543784.2021.1901883>
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074648/>
 15. Lyng, G, Sheils N, Kennedy C, Griffin DO, Berke E. **Identifying Optimal COVID-19 Testing Strategies for School and Businesses: Balancing testing frequency, individual test technology, and cost.** PLOS ONE 2021 Mar 25; 16(3): e0248783. doi:10.1371/journal.pone.0248783. PMID: 33764982
<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0248783>
 16. Daniel O. Griffin, Denise Brennan-Rieder, Binh Ngo, Pierre Kory, Marco Confalonieri, Jose Iglesias, Michael Dube, Neha Nanda, Daniel Arkfeld, Diana Hanna, David Sawcer, David Peng, Preet Chaudhary, Eivind H. Vinjevoll, Cristina Mussini, Oriol Mitjà, Vincente Soriano, Nicolas Peschanski, António Lobo-Ferreira, Iraldo B. Rivero, Marc Rendell, Stephen Ditmore, Rajkumar Dasgupta, Gino In, Gilles Hayem, Leland Shapiro, Joseph Varon, Maria Carmela Piccirillo, Paul Marik. **The Importance of Understanding the Stages of COVID-19 in Treatment and Trials.** AIDS Rev 2021 2021/02/09. DOI: 10.24875/AIDSRev.200001261.
<https://pubmed.ncbi.nlm.nih.gov/33556957/>
 17. Griffin DO, Jensen A, Khan M, Chin J, Chin K, Saad J, Parnell R, Awwad C, Patel D **Cytokine storm of a different flavor: the different cytokine signature of SARS-CoV2 the cause of COVID-19 from the original SARS outbreak** -Journal of Global Antimicrobial Resistance (2020) doi: <https://doi.org/10.1016/j.jgar.2020.11.005>
<https://pubmed.ncbi.nlm.nih.gov/33242672/>

18. Shimotsu ST, Johnson ARL, Berke EM, Griffin DO. **COVID-19 infection control measures in long-term care facility, Pennsylvania, USA.** Emerg Infect Dis. 2021 Feb 2
<https://pubmed.ncbi.nlm.nih.gov/33211994/>
19. Adam Cuker, Eric Tseng, Robby Nieuwlaat, Panted Angchaisuksiri, Clifton Blair, Kathryn Dane, Jennifer Davila, Maria DeSancho, David Diuguid, Daniel Griffin, Susan Kahn, FA Klok, Alfred Lee, Ignacio Neumann, Ashok Pai, Menaka Pai, Marc Righini, Kristen Sanfilippo, Deborah Siegal, Mike Skara, Kamshad Touri, Elie Akl, Imad Bouakl, Mary Boulos, Romina Brignardello-Petersen, Rana Charide, Matthew Chan, Karen Dearness, Andrea Darzi, Philipp Kolb, Luis Lozano, Razan Mansour, Gian Paolo Morgano, Rami Morsi, Atefeh Noori, Thomas Piggott, Yuan Qiu, Yetiani Roldan, Finn Schünemann, Adrienne Stevens, Karla Solo, Matthew Ventresca, Wojtek Wiercioch, Reem A. Mustafa, and Holger J. Schünemann. **American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.** Blood Adv 2021; 5 (3): 872–888. doi:
<https://doi.org/10.1182/bloodadvances.2020003763>
20. Griffin DO, Jensen A, Khan M, Chin J, Chin K, Saad J, Parnell R, Awwad C, Patel D. **Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis.** Br J of Haematol 2020 May 6. Doi: 10.1111/bjh. 16792 <https://pubmed.ncbi.nlm.nih.gov/32374029/>
21. Griffin DO, Jensen A, Khan M, Chin J, Chin K, Saad J, Parnell R, Awwad C, Patel D. **Pulmonary embolism and increased levels of D-dimer in patients with coronavirus disease.** Emerg Infect Dis. 2020 Aug. <https://doi.org/10.3201/eid2608.201477>
<https://pubmed.ncbi.nlm.nih.gov/32348233/>
22. Sebrow J, Goff S.P., Griffin DO. **Successfully Transfected Primary Peripherally Mobilized Human CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs) Demonstrate Increased Susceptibility to Retroviral Infection** - Virology Journal (2020) 17:22 DOI:10.1186/s12985-020-1297-3 <https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-1297-3>
23. Natasha Spottiswoode, M.D., D.Phil., Susan L. Bartlett, D.V.M., Dipl. A.C.Z.M., Kenneth J. Conley, D.V.M., Dipl. A.C.V.P., Tracie A. Seimon, Ph.D. Daniel O. Griffin M.D., Ph.D., John M. Sykes IV, D.V.M., Dipl. A.C.Z.M. **ANALYSIS OF PLASMODIUM LINEAGES IDENTIFIED IN CAPTIVE PENGUINS (*SPHENISCIFORMES spp.*), EIDERS (*SOMATERIA spp.*), AND INCA TERNS (*LAROSTERNA INCA*) IN A NORTH AMERICAN ZOOLOGICAL COLLECTION** - Journal of Zoo and Wildlife Medicine (2019)12/2019 <https://pubmed.ncbi.nlm.nih.gov/32212557/>
24. Griffin DS, Muhlbauer G, and Griffin DO. **Adolescents trust physicians for vaccine information more than their parents or religious leaders.** Heliyon 4 (2018) e01006. DOI: 10.1016/j.heliyon.2018.201006. <https://pubmed.ncbi.nlm.nih.gov/30619955/>
25. Griffin DO, Metzger M, Bharti B, Dharsee A, Rico JC, McGowan J. **Co-infection with Hepatitis C Virus Increases Mortality in HIV-1 Infected Patients Through Increased Liver-Related Deaths Rather Than By Increasing Malignancy Related Deaths.** J AIDS and Clin Res 2016, 7:4.DOI: 10.1097/QAD.0000000000001646.
https://www.researchgate.net/profile/Daniel-Griffin-3/publication/302595680_Co-infection_with_Hepatitis_C_Virus_Increases_Mortality_in_HIV-1_infected_Patients_through_Increased_Liver-Related_Deaths_Rather_Than_By_Increasing_Malignancy_Related_Deaths/links/58ba0389a6fdcc2d14de44f1/Co-infection-with-Hepatitis-C-Virus-Increases-Mortality-in-HIV-1-infected-Patients-through-Increased-Liver-Related-Deaths-Rather-Than-By-Increasing-Malignancy-Related-Deaths.pdf
26. Griffin, DO, and Goff, S.P. **Restriction of HIV-1-based Lentiviral Vectors in Adult Primary Marrow-Derived and Peripheral Mobilized Human CD34+ Hematopoietic Stem and Progenitor Cells Occurs Prior to Viral DNA Integration.** Retrovirology 2016 (1);14. PMID

26945863, DOI: 10.1186/s12977-016-0246-0.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779582/>

27. Rico JC, Schwartz RM, McGowan J, Griffin DO. **The Presence of a Malignant Comorbidity is a Significant Predictor of Increased 30-Day Hospital Readmission Rates in HIV-1 Infected Individuals.** J AIDS and Clin Res 2015, 6:12. DOI: 10.4172/2155-6113.1000532 <https://www.hilarispublisher.com/open-access/the-presence-of-a-malignant-comorbidity-is-a-significant-predictor-of-increased-30day-hospital-readmission-rates-in-hiv1-infected-in-2155-6113-1000532.pdf>
28. Griffin DO, Metzger M, Poeth K, Deng K, Dharsee A, Rico JC, McGowan J. **Malignancies, Particularly B-Cell Lymphomas, Are a Frequent Cause of Mortality in Human Immunodeficiency Virus-1 Patients Despite Highly Active Antiretroviral Therapy.** *OFID* 2015,2:ofv147. DOI: 10.1093/ofid/ofv147 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630453/>
29. Cui X., Zhang L., Magli A. R., CATERA R., Yan X. J., Griffin DO, Rothstein T. L., Barrientos J., Kolitz J. E., Allen S. L., Rai K. R., Chiorazzi N. and Chu C. C. (2015) **Cytoplasmic myosin exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability.** Leukemia 2015 July 29. DOI: 10.1038/leu.2015.204. <https://www.nature.com/articles/leu2015204>
30. Griffin, DO, and Goff, S.P. **HIV-1 is Restricted Prior to Integration in Primary Cord-Derived Human CD34+ Cells.** J Virol 2015 May 20. Pii JVI.0.01044-15. <https://www.nature.com/articles/leu2015204>
31. Griffin, DO, Dharsee, A., Rico, J.C., McGowan, J., **The Increasing Frequency of Deaths Due to Malignancy in HIV+ Patients is Associated with Poor Viral Suppression, Low CD4 Counts, Decreased Vitamin D Levels and Integrase Inhibitor Therapy.** Journal of Health Science 2 (2014) 240-247. DOI: 10.17265/2328-7136/2014.05.005
32. Griffin, DO and T.L. Rothstein, **Human "orchestrator" CD11b(+) B1 cells spontaneously secrete IL-10 and regulate T cell activity.** Molecular Medicine, 2012 Sep 7;18:1003-8. PMID 22634719 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459484/>
33. Griffin, DO and T.L. Rothstein, **Human B1 cell Frequency: Isolation and Analysis of Human B1 Cells.** Frontiers in Immunology, 2012. 3(122): p. 1-10. Epub 2012 May 25. PMID 22634719 <https://www.frontiersin.org/articles/10.3389/fimmu.2012.00122/full>
34. Griffin, DO, T. Quach, F. Batliwalla, N.E. Holodick, and T.L. Rothstein. 2012. **Human CD11b+ B1 cells are not monocytes: A reply to "Gene profiling of CD11b+ and CD11b- B1 cell subsets reveals potential cell sorting artifacts".** J Exp Med. 209:434-436. PMID 22412176 <https://rupress.org/jem/article/209/3/434/41323/Human-CD11b-B1-cells-are-not-monocytes-A-reply-to>
35. Griffin, DO, and T.L. Rothstein. 2011. **A small CD11b+ human B1 cell subpopulation stimulates T cells and is expanded in lupus.** J Exp Med. 208:2591-8. PMID 22110167 <https://rupress.org/jem/article/208/13/2591/41078/A-small-CD11b-human-B1-cell-subpopulation>
36. Griffin, DO, N.E. Holodick, and T.L. Rothstein. 2011. **Human B1 cells are CD3-: A reply to "A human equivalent of mouse B-1 cells?" and "The nature of circulating CD27+CD43+ B cells".** J Exp Med. 208:2566-9. PMID 22184682 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244032/>
37. Griffin, DO, N.E. Holodick, and T.L. Rothstein. 2011. **Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+CD70-.** J Exp Med. 208:67-80. PMID 21220451 <https://rupress.org/jem/article/208/2/409/40844/Human-B1-cells-in-umbilical-cord-and-adult>
38. Doing A, Griffin D, Jacobson JA, Amber IJ, Gilbert E. 2001. **B-cell function in chronic heart**

failure: antibody response to pneumococcal vaccine. J Card Fail 7:318-21. PMID 11782854
[https://onlinejcf.com/article/S1071-9164\(01\)19551-5/abstract](https://onlinejcf.com/article/S1071-9164(01)19551-5/abstract)

REVIEWS/COMMENTARIES

1. Griffin DO. **Commentary on Effectiveness of Nirmatrelvir-Ritronavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review** American Journal of Therapeutics 31(3):p e298-e299, May/June 2024. | DOI: 10.1097/MJT.0000000000001748
https://journals.lww.com/americantherapeutics/fulltext/2024/06000/commentary_on_effectiveness_of.10.aspx
2. Griffin DO. **The Challenge of Malignancies in HIV-1, Beyond Immune Activation and Back to Decreased Immune Surveillance.** J AIDS and Clin Res 2016, 7:1 p535
doi:10.4172/2155-613.1000535 <https://www.hilarispublisher.com/open-access/the-challenge-of-malignancies-in-hiv1-beyond-immune-activation-andback-to-decreased-immune-surveillance-2155-6113-1000535.pdf>
3. Rothstein, T.L., D.O. Griffin, N.E. Holodick, T.D. Quach, and H. Kaku. 2013. **Human B-1 cells take the stage.** *Annals of the New York Academy of Sciences* 2013 May;1285:97-114. PMID 23692567 <https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/nyas.12137>

BOOKS and CHAPTERS

1. Committee on Infectious Diseases; American Academy of Pediatrics; Red Book 2027 (Primary contributor and leading content expert for the chapter Parasitic Diseases-146.)
2. Textbook of SARS-CoV-2 and COVID-19: Epidemiology, Etiopathogenesis, Immunology, Clinical Manifestations, Treatment, Complications, and Preventive Measures 2024 Elsevier Inc. (Authored Chapter 4 COVID-19: Natural History and Spectrum of Disease and Chapter 18 Vaccine Basics and the Development and Rollout of COVID-19 Vaccines)
3. Committee on Infectious Diseases; American Academy of Pediatrics; Red Book 2021 (Primary contributor and leading content expert for the chapters Parasitic Diseases-150 and Enterobius vermicularis-159.)
4. Long S, Prober C, Fischer M (Griffin-Chapter on Tissue Nematodes). Principles and Practice of Pediatric Infectious Diseases, 6th Edition 2020 Expert Consult.
5. Griffin DO. The Medical Handbook for Limited Resource Settings V1. 2019 Parasites Without Borders, Inc, NY.
6. Despommier D, Griffin DO, Gwadz R, Hotez J, Knirsch C. Enfermedades Parasitarias Sexta Edición, 2017 Parasites Without Borders, Inc, NY.
7. Despommier D, Griffin DO, Gwadz R, Hotez J, Knirsch C. Parasitic Diseases 7th Edition, 2019 Parasites Without Borders, Inc, NY.
8. Despommier D, Griffin DO, Gwadz R, Hotez J, Knirsch C. Parasitic Diseases 6th Edition, 2017 Parasites Without Borders, Inc, NY.
9. Long S, Prober C, Fischer M (Griffin-Chapter on Tissue Nematodes). Principles and Practice of Pediatric Infectious Diseases, 5th Edition 2017 Expert Consult.
10. Griffin DO Babbitt NR, Collins D, Diamond LH, Drury BM, Duke JR, Heichert S, Jacobs BR, Loveys A, McColm D, Ott J, Schulte M, Wise PB, 2010, *Go-Live: Smart Strategies from Davies Award-Winning EHR Implementations*, Healthcare Information and Management Systems.

CASE REPORTS

1. Griffin, DO 2018. **The diagnosis of symptomatic acute antiretroviral syndrome during the window period with antigen/antibody testing and HIV viral load.** IDCases, 2018, May 23. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011141/>
2. Griffin, DO, Donaghy, H.J., Edwards, E. 2014. **Management of Serology Negative Human Hepatic Hydatidosis (Caused by Echinococcus Granulosis) in a Young Woman from Bangladesh in a Resource Rich Setting: A Case Report.** IDCases, 2014 March 2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735457/>

ABSTRACTS

1. 2019 Cold Spring Harbor Retroviruses Meeting *Abstract/Poster* **Electroporation nonspecifically increases susceptibility of CD34+ cells to retroviral infection.** Results of introduction of mRNA and siRNA into using electroporation introduction into primary hematopoietic human stem and hematopoietic progenitor cells on expression levels and lentiviral nuclear entry.
2. 2018 Cold Spring Harbor Retroviruses Meeting *Abstract/Poster* **Susceptibility of Human CD34+ Hematopoietic Stem and Progenitor Cells to HIV-1-based Lentiviral Vectors Correlates with expression of various Cellular Cytoskeleton Genes: THBS1, GDF15, TUBB1, KRT79, HDB, and SPTB** Results of an mRNAseq screen demonstrating that the levels of the mRNA coding for various cellular cytoskeletal and associated genes such as THBS1, GDF15, TUBB1, KRT79, HDB and SPTB implicated cytoskeletal stability in the the block to lentiviral nuclear entry.
3. 2017 Cold Spring Harbor Retroviruses Meeting *Abstract/Poster* **Susceptibility of Adult Peripheral Mobilized Human CD34+ Hematopoietic Stem and Progenitor Cells to HIV-1-based Lentiviral Vectors Correlates with Levels of Various Genes Involved in the Cellular Cytoskeleton** Further data on mRNA levels of cytoskeletal proteins from an RNAseq screen. Data using mRNA and siRNA in primary hematopoietic human stem and hematopoietic progenitor cells on expression levels and lentiviral nuclear entry.
4. 2014 Infectious Disease Society of New York Annual Meeting: Hot Topics in Infectious Diseases. Albert Einstein College of Medicine Montefiore Medical Center: *Speaker, Abstract* **Human Hematopoietic Stem Cells Block Retroviruses Prior to Integration** Identification of the block to HIV-1 that occurs prior to nuclear entry and early data on mRNA levels of cytoskeletal proteins from an RNAseq screen. Data using mRNA and siRNA in primary hematopoietic human stem and hematopoietic progenitor cells on expression levels and lentiviral nuclear entry.
5. 2014 Columbia University Stem Cell Initiative (CSCI) New York, NY *Speaker, Abstract* **Restriction Factors Limiting Human Lentiviral Vector Based Gene Therapy** March 2014 Discussion of the block to HIV-1 that occurs prior to nuclear entry.
6. 2014 New York City Epidemiology Forum: *Poster, Abstract* **Increasing Cancer Deaths in a Well Characterized HIV+ Cohort** A presentation on the actual impact of HIV on incidence of cancer and associated mortality in a research cohort of >15,000 people living with HIV.
7. 2013 Infectious Disease Society of New York Meeting. Albert Einstein College of Medicine Montefiore Medical Center: *Abstract and Poster* Presentation **Human "orchestrator" CD11b(+) B1 cells spontaneously secrete IL-10 and regulate T cell activity** Data comparing a subset of Human B1 cells that produce IL-10 and a comparison to identified IL-

- 10 producing B cells using different surface markers.
8. 2012 Immunotherapy 2012: Therapeutic Manipulation of the Inflammatory Microenvironment. Havana, Cuba. *Abstract and Speaker **Harnessing Natural Antibodies for Novel Therapeutics: The Potential Role of Human B1 Cells and Natural Antibodies in HIV Associated Malignancies*** Single cell sorting of Human B1 cells, amplification of mRNA encoding natural antibody immunoglobulins, cloning into DNA expression plasmids with production of mRNA resulting in production on cloned natural antibodies.
9. 2011 Keystone Conference B Cells: New Insights into Normal versus Dysregulated Function. Whistler, British Columbia, Canada. *Abstract, Poster, and Speaker **Human B1 Cells Effectively Target Streptococcus Pneumoniae*** Single cell sorting of Human B1 cells, amplification of mRNA encoding natural antibody immunoglobulins, and their analysis.
10. 2010 Mohonk Retreat -Feinstein Institute of Molecular Medicine- New Palz, NY. *Abstract, Poster **Human B1 Cells are Identified in Umbilical Cord Blood*** Shared data on the putative phenotype of Human B1-cells and comparison to prior suggested cel surface markers.

16-PRESENTATIONS (just some examples)

1. **Long COVID: An Evidenced-based Discussion** Maine Medical Association Annual Meeting Keynote Speaker, Bar Harbor, Maine September 2024
2. **An Introduction to Global Health** College of William and Mary July 2024
3. **Long COVID** Southeastern AIDS Education and Training Center, Kentucky August 2024
4. **Global Health Cases from around the World** (University of Glasgow-DTMH program) Glasgow Scotland-January 2024
5. **What Does our COVID Future Look Like** (Keynote Speaker at the Hilcrest Sundance 2023) February 2023
6. **Global Health Cases from around the World** (University of Glasgow-DTMH program) Glasgow Scotland-January 2023
7. **Cases from around the World** (University of Glasgow-DTMH program) Glasgow Scotland-January 2022
8. **Cases from around the World** (University of Glasgow-DTMH program) Glasgow Scotland-January 2021
9. **COVID-19: Understanding the Disease Impacts** (International Affairs Conference of Star Island) Providing information on COVID-19 missteps in NY, clinical phases, testing, and approaches to school openings.
10. **COVID-19: The Health Crisis and Community** (University of California, Santa Barbara) May 2020 Providing information on COVID-19 relevant to University Communities
11. **Guidance for COVID-19** (ProHealth Care Associates) March 2020 Hosted Webinars providing guidance, scripting, and information to hundreds of clinicians on the latest information on SARS-CoV2 and care of potentially infected patients.
12. **Cases from around the World** (University of Glasgow-DTMH program) Glasgow Scotland-January 2020
13. **Cases from Southeast Asia** (University of Glasgow-DTMH program) Glasgow Scotland-January 2020
14. **Cases from India** (University of Glasgow-DTMH program) Glasgow Scotland-January 2020
15. **Cases from Central and South America** (University of Glasgow-DTMH program) Glasgow Scotland-January 2020
16. **Cases from Africa** (University of Glasgow-DTMH program) Glasgow Scotland-January 2020
17. **Case** (University of Glasgow-DTMH program) Glasgow Scotland-January 2020

18. **Lice and Scabies** (Plainview Hospital Northwell Residency Program) Plainview, NY-January 2020
19. **Lecture Series – Medical Care in Resource Limited Settings (Sexually transmitted Diseases, Cholera, Dehydration, Tuberculosis, Upper Respiratory Infections, and Lower Respiratory Infections)** (Foundation International Medical Relief of Children (FIMRC)) Bududa, Uganda-November 2019
20. **Parasitic Diseases** (Floating Doctors 3/2019)
21. **Cases from around the World** (University of Glasgow-DTMH program) Glasgow Scotland-January 2019
22. **Cases from Southeast Asia** (University of Glasgow-DTMH program) Glasgow Scotland-January 2019
23. **Cases from India** (University of Glasgow-DTMH program) Glasgow Scotland-January 2019
24. **Cases from Central and South America** (University of Glasgow-DTMH program) Glasgow Scotland-January 2019
25. **Cases from Africa** (University of Glasgow-DTMH program) Glasgow Scotland-January 2019
26. **Rational Approach to Antibiotic Utilization in a Resource Limited Region of Uganda** (Foundation International Medical Relief of Children (FIMRC)) Bududa, Uganda-December 2018
27. **Approaches to Management of Stroke and Hypertension in a Resource Limited Region of Uganda** (Foundation International Medical Relief of Children (FIMRC)) Bududa, Uganda-November 2018
28. **Susceptibility of Human CD34+ Hematopoietic Stem and Progenitor Cells to HIV-1-based Lentiviral Vectors Correlates with the Expression of Various Cellular Cytoskeleton Genes** Discussion of the block to HIV-1 that occurs prior to nuclear entry and the identification of mRNA levels of cytoskeletal proteins from an RNAseq screen. Preliminary data was shared regarding the impact of the introduction of mRNA and siRNA into the primary hematopoietic human stem and hematopoietic progenitor cells on expression levels and lentiviral nuclear entry. (Columbia University Stem Cell Initiative (CSCI) NY, NY 4/2018)
29. **Parasitic Diseases** High-level review of major parasitic diseases impacting humans with focus on those seen in remote sections of Panama (Floating Doctors 3/2018)
30. **Introduction to Leishmaniasis** (Floating Doctors 10/2017)
31. **Cutaneous Leishmaniasis** (Floating Doctors 10/2017)
32. **Mucocutaneous Leishmaniasis** (Floating Doctors 10/2017)
33. **Melioidosis: Clinical Aspects** (University of Minnesota Global Health Course 5/2017)
34. **HTLV-1: A Clinical Perspective and Basic Science** (University of Minnesota Global Health Course 5/2017)
35. **HIV Prevention: Focus on the Dominican Republic and Haiti** (University of Minnesota Global Health Course 5/2017)
36. **Chief Complaints in the Developing World: Clinical Cases** (University of Minnesota Global Health Course 5/2017)
37. **Chief Complaints FROM the Developing World: Clinical Cases** (University of Minnesota Global Health Course 5/2017)
38. **HTLV-1 Diagnosis and Management** (Columbia University Department of Medicine, Division of Infectious Diseases December 2016)
39. **Hepatitis B and SIDA** (Foundation International Medical Relief of Children (FIMRC)) Restaurción, Dominican Republic December 2016
40. **Diabetic Foot Infections** (Foundation International Medical Relief of Children (FIMRC)) Restaurción, Dominican Republic -November 2016
41. **HIV Diagnosis and Management** Columbia University Department of Medicine -Spring 2015

42. **Infections Associated with Outdoor Exposures** (Lecture NSLIJHS ID Division May 2014)
43. **Management of Serology Negative Human Hepatic Hydatidosis (Caused by Echinococcus Granulosis) in a Young Woman from Bangladesh in a Resource Rich Setting: A Case Report** Importance of recognizing serology negative presentations and their management. (Presentation at Long Island Infection Disease Society March 2014)
44. **Dengue/Chikungunya** Focus on the basic virology, epidemiology, clinical presentations, the role and mechanisms of antibody-dependent enhancement (ADE), management, and vaccine development challenges (Lecture NSLIJHS ID Division January 2014)
45. **Sepsis** (Lecture NSLIJHS Internal Medicine House Staff January 2014)
46. **Tuberculosis: Presentation, Diagnosis, and Treatment** (Lecture NSLIJHS ID Division October 2013)
47. **Leptospira/Lyme and other Borrelia: Clinical Manifestation, Diagnosis and Treatment** (Lecture NSLIJHS ID Division June 2013)
48. **Hemorrhagic Fevers: Arenaviruses, Bunyaviruses, Flaviviruses, and Filoviruses** (Lecture NSLIJHS ID Division April 2013)

DISASTER/OVERSEAS EXPERIENCE/GLOBAL HEALTH TRAINING/EXPERIENCE

- Floating Doctors/Remote Care Education –December 2023 –primary care to isolated indigenous population on islands of the coast of *Panama* only accessible by water.
- Foundation for International Medical Relief of Children (FIMRC) Bududa, *Uganda*, clinical care and teaching December 2023.
- Foundation for International Medical Relief of Children (FIMRC) Bududa, *Uganda*, clinical care and teaching December 2022.
- TROPMEDEX – Visiting hospitals, clinics, research centers, and villages in *Uganda*, seeing patients and meeting with clinicians. December 2022.
- OPTUM COVID-19 Response Core Team March 2020-2023 The Infectious Disease Physician on the Core Team managing the response of OPTUM Tristate (the largest physician-owned multispecialty practice in the U.S. ~3,000 physicians, 2-3 million patients in NYC-tristate area) (working the dissemination of information, updating clinicians on the appropriate response, creating scripting for offices, urgent care centers and phone triage and guidance on management).
- Floating Doctors/Remote Care Education –March 2022 –primary care to isolated indigenous population on islands of the coast of *Panama* only accessible by water.
- TROPMEDEX – Visiting hospitals, clinics, research centers, and villages in *Ghana*, seeing patients and meeting with clinicians. January-February 2022.
- Foundation for International Medical Relief of Children (FIMRC) Bududa, *Uganda*, near the Kenyan border, clinical care and teaching November 2019.
- Floating Doctors/Remote Care Education –March 2019 –primary care to isolated indigenous population on islands of the coast of Northern *Panama* only accessible by water.
- Foundation for International Medical Relief of Children (FIMRC) Bududa, *Uganda*, near the Kenyan border, clinical care and teaching November 2018-December 2018.
- Floating Doctors/Remote Care Education –March 2018 –primary care to isolated indigenous population on islands of the coast of Northern *Panama* only accessible by water.
- Floating Doctors –October 2017 –primary care to the isolated indigenous population on islands of the coast of Northern *Panama* only accessible by water.
- Foundation for International Medical Relief of Children (FIMRC) *Dominican Republic* near the Haitian border, clinical care and teaching November 2016-December 2016.

- Asian Tropical Medicine Training (Bangkok, *Thailand*, and Siem Reap, *Cambodia*) July 2016-August 2016.
- Christian Medical College Infectious Diseases Training and Research Center, (Vellore, *India*) International Short Course in Clinical Tropical Medicine November 2015.
- Gorgas Institute Advanced Course in Clinical Tropical Medicine (Lima, *Peru*) August 2015.
- University of Minnesota Global Health Course: Clinical Tropical, Migrant and Travel Medicine- (8-module course including an overseas module in southeast Asia-ASTMH approved course for eligibility for the ASTMH Examination in Clinical Tropical Medicine and Traveler's Health via the Diploma Course pathway) completed August 2016
- Triage and performance of Infectious Disease Care during Hurricane Sandy and following in the New York Area October 2012-February 2012 NSLIJHS Health System
- Site Visit Kamuzu Central Hospital, Light House Trust HIV Clinic (Lilongwe, *Malawi*) 1/2014
- Clinical Rotation Bir Hospital (Kathmandu, *Nepal*) 1/31/1994-2/26/1994

STATES WITH CURRENT ACTIVE MEDICAL LICENSURE

- New York 11/07/2007-current until 06/30/2025

CLINICAL TRIALS

- At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19 (1/4/2021-4/18/2021) enrollment 4000-participants ID:2020-0081 ClinicalTrials.gov Identifier NCT4656691role: Principal Investigator
 - Open-label, pragmatic, single-dose study using matched controls in participants with mild to moderate COVID-19. Participants will track for developing symptoms while at home and, upon reporting symptoms, will test for COVID-19. If positive for COVID-19, a one-time at-home infusion of Bamlanivimab (LY3819253) will be provided by Optum Infusion. Participants will then be tracked for 28 days to assess for any additional medical care needed or if hospitalization is required.
- PATCH 2&3: Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine (4/7/2020-7/11/2020) ClinicalTrials.gov Identifier NCT04353037 Role: Principal Investigator
 - The proposed hypothesis is that high doses of hydroxychloroquine (HCQ) for at least two weeks can be effective antiviral medication both as a treatment in ambulatory patients and prophylaxis/treatment in health care workers because it impairs lysosomal function and reorganizes lipid raft (cholesterol and sphingolipid rich microdomains in the plasma membrane) content in cells, which are both critical determinants of Emerging Viral Disease (EVD) infection. This hypothesis is based on a growing literature linking chloroquine to antiviral activity. It is estimated that enough information exists to launch a clinical trial of hydroxychloroquine for COVID-19.
- Investigations Regarding B-cell Subsets in Humans (6/23/2009-8/26/2015) ClinicalTrials.gov Identifier NCT00926692 role: Principal Investigator
 - The specific aim of this research project is to define the human equivalent of mouse B1 cells. This will be done by evaluating IgM secretion, surface markers, functional characteristics, V gene usage, N-region addition, and phosphorylation status of intracellular proteins, gene expression, sequencing of immunoglobulin genes, determination of antigenic specificity, replication history, and response to different

stimuli. This project aims to begin translating decades of basic science research and research in the mouse model into the human system. Properly defining this B cell subset in humans is believed to lead to better therapeutics, prognostics, and prevention for several diseases, including infections, autoimmune diseases, and cancer.

SUBJECT MATTER EXPERT/EXPERT WITNESS/LEGAL CONSULTING

- Subject matter expert, expert testimony, and review of medical cases for evaluation of deviation from the standard of care and deviation from evidence-based care